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Abstract
Background: Acinetobacter baumannii has emerged as a major nosocomial pathogen worldwide.
Many of the circulating strains exhibit multi-drug resistance remaining consistently susceptible only
to polymyxins. In-vitro  studies have reported that polymyxins combined with carbapenems,
rifampicin or azithromycin are synergistic against these strains despite in-vitro resistance to these
agents alone. The use of antimicrobial combinations have therefore been advocated for the
treatment of severe A. baumannii infection in man. In order to determine whether such
combinations are synergistic against the prevalent clones of multi-drug resistant A. baumannii
causing infection in the UK, we performed synergy testing against representative isolates using two
rapid Etest methods.
Methods: The activity of polymyxin in combination with imipenem, azithromycin or rifampicin was
assessed against five strains of multi-drug resistant A. baumannii encoding OXA-23 carbapenemases.
Synergy studies were performed by Etest-agar dilution and a combined Etest strip method. Synergy
was defined as a FICI of ≤ 0.5.
Results: All strains were resistant to β-lactams, carbapenems, quinolones and aminoglycosides but
susceptible to polymyxins. Marked synergy was not seen with polymyxin in combination with
imipenem, rifampicin or azithromycin against any of the strains. Borderline synergy (FICI = 0.5) was
seen against one strain belonging to OXA-23 clonal group 2, using the Etest-agar dilution method
only.
Conclusion:  In-vitro  synergy with polymxyin in combination with imipenem, rifampicin or
azithromycin is highly strain and method dependent. As reliable synergy could not be demonstrated
against the prevalent UK multi-drug resistant strains, use of such combinations should not be used
for empirical treatment of these infections in the UK. The optimal treatment for serious multi-drug
A. baumannii infection and the role of combination therapy should be addressed in a prospective
clinical trial.
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Background
Acinetobacter baumannii has emerged as an important
nosocomial pathogen causing ventilator associated pneu-
monia, bacteraemia and sepsis in the critically ill. Several
strains exhibiting multi-drug resistance have been associ-
ated with ongoing outbreaks of infection in intensive care
units in London and the South East of England which
have proved extremely difficult to treat and control. These
strains, designated OXA-23 clone 1 and OXA-23 clone 2
are resistant to all β-lactams (including carbapenems),
fluoroquinolones and most aminoglycosides, remaining
consistently susceptible only to polymyxin [1]. Many
patients have therefore undergone treatment with the pol-
ymyxin E formulation, colistin although there is little data
on its efficacy in this setting. Colistin has limited tissue
penetration when administered intravenously and may
not achieve adequate concentrations in important foci of
A. baumannii infection such as the respiratory tract [2]. It
is also only weakly bactericidal at low concentrations ver-
sus A. baumannii in-vitro [3]. The activity of an antimicro-
bial agent can sometimes be enhanced by the use of
another agent with a different mode of action in combina-
tion. Recently polymyxin with imipenem and rifampicin
and polymyxin with meropenem, rifampicin or azithro-
mycin were reported as combinations with significant in-
vitro activity against multi-drug resistant strains of A. bau-
mannii [4,5]. We set out to confirm this finding by deter-
mining the in-vitro activity of polymyxin in combination
with imipenem, rifampicin or azithromycin versus epi-
demic clones of A. baumannii producing OXA-23 carbap-




Five multidrug resistant strains of A. baumannii known to
produce OXA-23 carbapenemases were obtained from the
Epidemiological Typing Reference Unit at the Health Pro-
tection Agency (HPA, Colindale, UK). The strains were
confirmed as A. baumannii by biochemical profiling using
API 20NE strips (Biomerieux, Marcy d'Etoile, France) and
confirmed as resistant to ampicillin, cefotaxime, ceftazi-
dime, ciprofloxacin, piperacillin/tazobactam, gentamicin,
amikacin and imipenem by the British Society for Antimi-
crobial Chemotherapy (BSAC) disc diffusion method [6].
As the OXA 23 clones make up approximately 86% of all
carbapenem resistant strains of A. baumannii refered to the
HPA since 2000 [7] the isolates used in this study are rep-
resentative of the epidemic UK clones.
Antimicrobial agents
Polymyxin was obtained from Sigma (Poole, Dorset) and
Etest strips from AB Biodisk (Solna, Sweden). All testing
was carried out in Isosensitest agar (Oxoid, Basingstoke,
UK). The MICs to polymyxin were determined by Etest
and agar dilution and the MICs to imipenem, rifampicin
and azithromycin by Etest.
Synergy assays
For synergy screening by Etest – agar dilution, polymyxin
was incorporated into Isosensitest agar at 0.25 X the agar
MIC for each strain tested. Plates were inoculated with 0.5
McFarland suspensions of each isolate and imipenem,
rifampicin or azithromycin Etest strips applied. Following
incubation for 24 hrs at 37°C the strips were read and the
Etest MICs compared to a series performed in the absence
of polymyxin. Synergy screening was also performed
using a method employing two Etests applied at right
angles to each other, as described by Bonapace et al. [8].
Plates were set up with the Etests intersecting at the MIC
of each agent tested, inoculated and incubated as above.
Fractional inhibitory concentration indices (FICIs) were
calculated as MIC of drug X (in combination) / MIC of
drug X alone + MIC of drugY (in combination) / MIC of
drugY alone. Synergy between agents was defined as a FICI
≤ 0.5.
Results
Four of the isolates were members of OXA-23 clone 1 and
the other was a member of OXA-23 clone 2. The MIC's of
all five isolates to imipenem, rifampicin, polymyxin and
azithromycin are shown in Table 1. Using the Etest-agar
dilution method imipenem in combination with poly-
myxin resulted in a reduction in the imipenem MIC for
two out of five strains with synergy (FICI = 0.5) observed
for the OXA-23 clone 2 strain. Rifampicin in combination
with polymyxin led to reduced MICs with all strains by
Etest-agar dilution but this was not synergistic for OXA-23
clone 1 isolates (FICI = 0.625 - 0.75) and only borderline
for the OXA-23 clone 2 strain (FICI = 0.5). Synergy was
Table 1: Characteristics of A. baumannii isolates
Strain Clonal Group Polymyxin MIC (mg/L) Imipenem MIC (mg/L) Rifampicin MIC (mg/L) Azithromycin MIC (mg/L)
1 OXA-23 clone 1 0.25 12 4 32
2 OXA-23 clone 1 0.25 >32 4 >256
3 OXA-23 clone 1 0.25 >32 4 >256
4 OXA-23 clone 1 0.25 >32 4 >256
5 OXA-23 clone 2 0.25 >32 4 24Annals of Clinical Microbiology and Antimicrobials 2006, 5:10 http://www.ann-clinmicrob.com/content/5/1/10
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not observed using polymyxin in combination with azi-
thromycin. Using two Etests to screen for synergy, no
reduction in imipenem, rifampicin or azithromycin MIC
was observed for any of the OXA-23 clone 1 isolates. A
reduction in the rifampicin MIC to 2 mg/L and the poly-
myxin MIC to 0.125 mg/L was seen for the OXA-23 clone
2 isolate when these agents were used in combination
(Figure 1). Likewise the azithromycin MIC fell to 12 mg/L
and the imipenem MIC to 24 mg/L when used in combi-
nation with polymyxin. None of these combinations
however resulted in synergy versus OXA-23 clone 2 (FICI
≥ 1).
Discussion
The problem of multi-drug resistance in clinical isolates of
A. baumannii has led to widespread use of polymyxins for
the treatment of severe infections with this organism. Sev-
eral studies have evaluated the ability of other agents to
produce synergy when combined with polymyxin in-vitro
[4,5]. The aims of the present study were therefore two-
fold; firstly to determine the in-vitro efficacy of polymyxin
in combination with other agents against epidemic UK A.
baumannii clones, and secondly, to evaluate the use of
rapid methods of testing antibiotic synergy which could
be employed in routine clinical practice.
We were unable to show synergy with either imipenem,
rifampicin or azithromycin in combination with poly-
myxin for any of the OXA-23 clone 1 isolates. For the
OXA-23 clone 2 isolate synergy was observed (FICI = 0.5)
with polymyxin in combination with rifampicin or imi-
penem The clinical relevance of this synergy can be
debated as the MIC to imipenem in combination with
polymyxin was still 8 mg/L which is still above the imi-
Activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus a multidrug resistant A Figure 1
Activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus a multidrug resistant A. baumannii 
OXA-23 clones using 2 Etest method. A) Polymyxin and imipenem versus OXA-23 clone 2, B) Polymyxin and rifampicin versus 
OXA-23 clone 2, C) Polymyxin and azithromycin versus OXA-23 clone 1Annals of Clinical Microbiology and Antimicrobials 2006, 5:10 http://www.ann-clinmicrob.com/content/5/1/10
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penem break point of 4 mg/L. As the isolates used in this
study are the prevalent multi-drug resistant strains in the
United Kingdom this has implications for the use and
selection of combination antimicrobial regimens for
empirical treatment of these infections. In the study by
Timurkaynak et al testing for synergy between colistin,
rifampicin, meropenem and azithromycin [5], synergy
with colistin and meropenem was seen versus two iso-
lates. The five strains used in this study however were not
uniformly resistant to carbapenems as those seen in the
UK (meropenem MIC 1 – 64 mg/L). Amongst the isolates
where synergy was demonstrated with meropenem the
isolates had meropenem MICs of 2 and 4 mg/L. These
would be considered sensitive using BSAC (sensitive ≤ 4)
[6] or intermediate (resistant =16) by the US CLSI [9] rec-
ommendations on meropenem breakpoints, suggesting
that synergy can be obtained with carbapenems in combi-
nation with colistin if resistance to carbapenems is only at
a low level. Hence in our study using isolates with high
level carbapenem resistance (MIC > 32 mg/L) synergy was
not observed using imipenem in combination with poly-
myxin.
In contrast to our findings, a study comparing checker-
board FICI determination with time kill assays on eight A.
baumannii isolates with high level imipenem resistance
(MIC = 32 mg/L) did demonstrate synergy between poly-
myxin B in double and triple combinations with imi-
penem and rifampicin [4]. However, in this instance an
incorrect interpretation of ∑FICs lead to erroneous con-
clusions being drawn. Although synergy versus all of the
isolates with the triple combination and against seven
with double combinations was reported, a FICI of ≤ 1 was
used as indicative of synergy.
This definition is generally considered too relaxed [10],
and if the more stringent definition (FICI ≤ 0.5) is applied
only three of the double and two of the triple combina-
tions would be considered synergistic, although, interest-
ingly one of these is between polymyxin B and imipenem.
Whilst most synergy studies have been performed using
checkerboard or time kill assays these methods are too
time consuming and technically challenging for routine
clinical testing. Our decision to use Etest was therefore
based on its ease of use and availability to routine clinical
laboratories. As Etests deliver a controlled concentration
gradient of antibiotic into the agar, errors in the prepara-
tion of the media and antibiotic dilutions required for
synergy testing using checkerboard and time kill method-
ology are avoided. In a comparison of Etest, time kill and
checkerboard assays using ten strains of Acinetobacter bau-
mannii  and the antibiotics piperacillin, trovofloxacin,
cefipime and tobramycin, Etest was noted to be more con-
servative in detecting synergy than either of the other two
methods [8]. Although this suggests that Etest may not be
effective in detecting weak synergy, it is debatable what, if
any, clinical significance detection of such activity may
have. The ability of Etest to rapidly detect only marked
synergy is likely to be far more useful in aiding the selec-
tion of antimicrobials combinations for the treatment of
multidrug resistant infections. A novel combination gra-
dient test, Xact™ has recently been developed by AB Bio-
disk. This uses perpendicularly aligned concentration
gradients of antibiotics embedded in a plastic carrier, for
direct application to an agar surface. A colistin –
rifampicin Xact™ test was used to quantify synergy
between colistin and rifampicin against six strains of car-
bapenem resistant A. baumannii [11]. Synergy was
reported against these strains and there was good con-
cordance between checkerboard and the Etest-agar dilu-
tion method. The Xact™ test may therefore be a useful
method for screening for strain dependent synergy of
agents in combination against clinical isolates of A. bau-
mannii.
There are very few studies of the efficacy of combination
regimens identified by in-vitro synergy screening in the
treatment of multi-drug resistant Acinetobacter infections.
A favourable outcome based on eradication of A. bauman-
nii  from clinical samples, was reported for 26 patients
with  A. baumannii ventilator associated pneumonia,
bacteraemia and meningitis when colistin was used in
combination with rifampicin [12]. This study did not
however assess patient outcome or compare the efficacy of
colistin alone. No data was reported on the in-vitro activity
of the agents in combination and whether there was in-
vitro synergy against the infecting strains by any method.
It is therefore difficult to determine whether the reported
efficacy should be ascribed to colistin alone, true in-vivo
Table 2: Polymyxin synergy with imipenem, rifampicin and azithromycin by Etest – agar dilution
Strain Imipenem MIC with 
polymyxin 0.25 × MIC (mg/L)
FICI Rifampicin MIC with 
polymyxin 0.25 × MIC (mg/L)
FICI Azithromycin MIC with 
polymyxin 0.25 x MIC (mg/L)
FICI
1 6 0.75 1.5 0.625 24 1
2 >32 1.00 1.5 0.625 >256 1
3> 3 2 1 . 0 02 0 . 7 5 > 2 5 6 1
4 >32 1.00 1.5 0.625 >256 1
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synergy between colistin and rifampicin or some unre-
lated effect of rifampicin such as immunomodulation. As
we have not been able to demonstrate consistent synergy
between polymyxin and rifampicin against isolates in the
UK exhibiting high level carbapenem resistance we would
not advocate empirical use of such a combination unless
this can be shown on a strain by strain basis. The optimal
treatment of multi-drug resistant Acinetobacter infections
should now be addressed via a well designed randomised
controlled clinical trial.
Conclusion
The optimal treatment of multi-drug resistant Acineto-
bacter infections remains controversial. Despite reports of
enhancedactivity of polymyxin combined with imi-
penem, rifampicin or azithromycin we were unable to
detect reliable in-vitro synergy between polymyxin B and
any of these agents versus epidemic strains of A. baumannii
with high level carbapenem resistance due to OXA-23 car-
bapenemases. At present we do not advocate empirical
use of these combination regimens in the UK until more
clinical data on their efficacy is available.
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